螺内酯治疗急性心力衰竭患者的疗效与安全性：一项系统评价方案
Efficacy and safety of spironolactone for the treatment of patients with acute heart failure: A protocol for systematic review.
作者信息
Feng Yan-Lin, Lu Min
机构信息
Department of Geriatrics, Yan'an People's Hospital, Yan'an.
Department of Cardiology, School Hospital of Xi'an International Studies University, Xi'an, Shaanxi, China.
出版信息
Medicine (Baltimore). 2020 Oct 23;99(43):e22590. doi: 10.1097/MD.0000000000022590.
BACKGROUND
This study will investigate the efficacy and safety of spironolactone for the treatment of acute heart failure (AHF).
METHODS
The following electronic databases will be retrieved in PUBMED, EMBASE, Cochrane Library, Web of Science, CINAHL, CBM, CNKI, and VIP database from inception through present. Two researchers will independently screen and assess the obtained literatures and extract outcome data. All study methodological quality will be assessed using Cochrane risk of bias tool, and all statistical analysis will be performed by RevMan 5.3 software. Additionally, we will undertake a narrative synthesis if it is possible.
RESULTS
This study will sum-marize most recent evidence to investigate the efficacy and safety of spironolactone for the treatment of AHF.
CONCLUSION
This study will seek to assess the efficacy and safety of spironolactone for treating AHF.
SYSTEMATIC REVIEW REGISTRATION
INPLASY202070053.
背景
本研究将调查螺内酯治疗急性心力衰竭（AHF）的有效性和安全性。
方法
从创刊至目前，在PUBMED、EMBASE、Cochrane图书馆、科学网、CINAHL、CBM、CNKI和维普数据库中检索以下电子数据库。两名研究人员将独立筛选和评估所获得的文献，并提取结果数据。所有研究方法的质量将使用Cochrane偏倚风险工具进行评估，所有统计分析将由RevMan 5.3软件进行。此外，如果可能，我们将进行叙述性综合分析。
结果
本研究将总结最新证据，以调查螺内酯治疗AHF的有效性和安全性。
结论
本研究将试图评估螺内酯治疗AHF的有效性和安全性。
系统评价注册
INPLASY202070053。
Zotero 插件